General Information of the Compound
Compound ID
CP0459454
Compound Name
AZD-2624
    Show/Hide
Synonyms
3-[(methanesulfonyl)amino]-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
3U471ZVC5K
4-Quinolinecarboxamide, 3-((methylsulfonyl)amino)-2-phenyl-N-((1S)-1-phenylpropyl)-
941690-55-7
AKOS032946112
AZ124752520
AZD-2624
AZD2624
BDBM50180193
CHEBI:140478
CHEMBL3545233
CS-7979
DB11692
GTPL5775
HY-14432
KB-74807
MLE4901
Pavinetant
Pavinetant [USAN]
QYTBBBAHNIWFOD-NRFANRHFSA-N
SCHEMBL3587478
UNII-3U471ZVC5K
pavinetantum
    Show/Hide
Structure
Formula
C26H25N3O3S
Molecular Weight
459.571
Canonical SMILES
CC[C@H](NC(=O)c1c(NS(C)(=O)=O)c(nc2ccccc12)-c1ccccc1)c1ccccc1
    Show/Hide
InChI
InChI=1S/C26H25N3O3S/c1-3-21(18-12-6-4-7-13-18)28-26(30)23-20-16-10-11-17-22(20)27-24(19-14-8-5-9-15-19)25(23)29-33(2,31)32/h4-17,21,29H,3H2,1-2H3,(H,28,30)/t21-/m0/s1
    Show/Hide
InChIKey
QYTBBBAHNIWFOD-NRFANRHFSA-N
CAS
941690-55-7
Physicochemical Property
logP
5.1544
Rotatable Bonds
7
Heavy Atom Count
33
Polar Areas
88.16
Hydrogen Bond Donor Count
2
Hydrogen Bond Acceptor Count
4
Complexity
33

"RO5" indicates the cutoff set by lipinski's rule of five:

(1) Molecular weight less than 500 Dalton;

(2) xlogp less than 5;

(3) No more than 5 hbonddonor (Hydrogen Bond Donor Count);

(4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count);

(5) No more than 10 rotbonds (Rotatable Bond Count).

    Show/Hide
Click to Show/Hide the External Link(s) of This Compound
PubChem ID
CID: 23649245
SID: 46520831
ChEMBL ID
CHEMBL3545233
DrugBank ID
DB11692
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound

Compound
Cell Line
Protein

Bioactivity Value:

<= 0.1 μM
> 0.1 μM and <= 10 μM
> 10 μM
Imprecise Activity
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01199, Neuromedin-K receptor
Cell-based Assay
Cell Line ID Cell Line Name Cell Line Organism
CL000011 CHO Cricetulus griseus (Chinese hamster)  1
1
IC50 = 1.6 nM
   TI
   LI
   LO
   TS
Clinical Information about the Compound
Drug 1 ( AZD2624 )
Drug Name AZD2624
Company AstraZeneca
Indication
Multiple sclerosis
Phase 2
Schizophrenia
Phase 2
Discontinued in Phase 2
Target(s)
Neuromedin-K receptor (TACR3)
Modulator